Updated results from pivotal phase III EXTEND clinical trial of pixantrone announced

[News]

Cell Therapeutics, Inc. ("CTI") announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies.

More... (http://www.news-medical.net/news/20091207/Updated-results-from-pivotal-phase-III-EXTEND-clinical-trial-of-pixantrone-announced-at-ASH-annual-meeting.aspx)